Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers
暂无分享,去创建一个
A. Wilde | R. D. de Boer | M. P. van den Berg | B. Bouma | F. Asselbergs | P. Doevendans | A. Teske | M. Cramer | K. Taha | W. T. te Rijdt | T. E. Verstraelen | Rianne H. de Bruin-Bon | R. de Brouwer | T. Verstraelen | W. P. te Rijdt | Rianne H A C M de Bruin-Bon | R. A. de Boer
[1] A. Wilde,et al. Early Mechanical Alterations in Phospholamban Mutation Carriers: Identifying Subclinical Disease Before Onset of Symptoms. , 2020, JACC. Cardiovascular imaging.
[2] F. Zannad,et al. Left ventricular myocardial deformation pattern, mechanical dispersion, and their relation with electrocardiogram markers in the large population-based STANISLAS cohort: insights into electromechanical coupling. , 2020, European heart journal cardiovascular Imaging.
[3] F. Asselbergs,et al. Evaluation of Disease Progression in Arrhythmogenic Cardiomyopathy: The Change of Echocardiographic Deformation Characteristics Over Time. , 2020, JACC. Cardiovascular imaging.
[4] T. Edvardsen,et al. Prediction of Ventricular Arrhythmias With Left Ventricular Mechanical Dispersion: A Systematic Review and Meta-Analysis. , 2020, JACC. Cardiovascular imaging.
[5] Y. Pinto,et al. Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular Imaging. , 2019, European heart journal cardiovascular Imaging.
[6] R. Hauer,et al. The Netherlands Arrhythmogenic Cardiomyopathy Registry: design and status update , 2019, Netherlands Heart Journal.
[7] B. Gerber,et al. Myocardial strain imaging: review of general principles, validation, and sources of discrepancies , 2019, European heart journal cardiovascular Imaging.
[8] Karim Taha,et al. The Prognostic Value of Right Ventricular Deformation Imaging in Early Arrhythmogenic Right Ventricular Cardiomyopathy. , 2019, JACC. Cardiovascular imaging.
[9] R. N. Planken,et al. Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging , 2019, European heart journal cardiovascular Imaging.
[10] R. D. de Boer,et al. Prevalence and cardiac phenotype of patients with a phospholamban mutation , 2018, Netherlands Heart Journal.
[11] Thor Edvardsen,et al. Prediction of Life-Threatening Ventricular Arrhythmia in Patients With Arrhythmogenic Cardiomyopathy: A Primary Prevention Cohort Study. , 2018, JACC. Cardiovascular imaging.
[12] S. Heymans,et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. , 2016, European heart journal.
[13] Maja Cikes,et al. Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. , 2016, European heart journal.
[14] Victor Mor-Avi,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.
[15] G. Pedrizzetti,et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[16] R. Hauer,et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. , 2015, European heart journal.
[17] R. Hauer,et al. Outcome in Phospholamban R14del Carriers: Results of a Large Multicentre Cohort Study , 2014, Circulation. Cardiovascular genetics.
[18] J. G. Post,et al. Recurrent and founder mutations in the Netherlands—Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy , 2013, Netherlands Heart Journal.
[19] R. Hauer,et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy , 2012, European journal of heart failure.
[20] Wojciech Zareba,et al. Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, European heart journal.
[21] R. Hetzer,et al. Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. , 2009, Heart Rhythm.
[22] Kristina Hermann Haugaa,et al. Left ventricular mechanical dispersion by tissue Doppler imaging: a novel approach for identifying high-risk individuals with long QT syndrome , 2008, European heart journal.
[23] Pieter A Doevendans,et al. Cardiovascular Ultrasound BioMed Central Review , 2006 .
[24] B. Soliven,et al. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.
[25] G. Dorn,et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[26] E. Kranias,et al. Calcium: Phospholamban: a crucial regulator of cardiac contractility , 2003, Nature Reviews Molecular Cell Biology.
[27] J. Pernod,et al. [Assessment of left ventricular function by echocardiography]. , 1976, Coeur et medecine interne.